Get started
MARVEL BIOSCIENCES CORPMM

MARVEL BIOSCIENCES CORP

0.105CADD
−0.005−4.55%
At close at May 30, 19:07 GMT
CAD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

MRVL fundamentals

Key facts

Market capitalization‪5.74 M‬CAD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.04CAD
Founded2018
Employees (FY)—
CEOJoseph Roderick Matheson
Websitemarvelbiotechnology.com
About

Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. It develops several patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The company was founded on June 14, 2021 and is headquartered in Calgary, Canada.

Ownership
‪‪52.20 M‬‬
Free Float shares
‪‪36.31 M‬‬ (69.55%)
Closely held shares
‪‪15.90 M‬‬ (30.45%)
Free Float shares
‪‪36.31 M‬‬ (69.55%)
Closely held shares
‪‪15.90 M‬‬ (30.45%)
Capital structure
Market cap
‪‪5.74 M‬‬
Debt
‪‪1.71 M‬‬
Cash & equivalents
‪‪59.53 K‬‬
Enterprise value
‪‪7.39 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪5.74 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
Q1 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25

Growth and Profitability

Company’s recent performance and margins

Performance
Q1 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−600.00 K‬‬
‪‪−450.00 K‬‬
‪‪−300.00 K‬‬
‪‪−150.00 K‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−600.00 K‬‬
‪‪−450.00 K‬‬
‪‪−300.00 K‬‬
‪‪−150.00 K‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−520.00 K‬‬
‪‪−390.00 K‬‬
‪‪−260.00 K‬‬
‪‪−130.00 K‬‬
‪0.00‬

Dividends

Dividend yield, history and sustainability

No dividends
MRVL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−600.00 K‬‬
‪0.00‬
‪‪600.00 K‬‬
‪‪1.20 M‬‬
‪‪1.80 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪600.00 K‬‬
‪‪1.20 M‬‬
‪‪1.80 M‬‬
‪‪2.40 M‬‬
Assets
Liabilities